Lenvaxen 10MG (Lenvatinib)

Basic Product Information of Lenvaxen (Lenvatinib) 10mg

How Lenvaxen (Lenvatinib) Works

Lenvaxen contains Lenvatinib, an oral multi-target kinase inhibitor that blocks a wide range of receptor tyrosine kinases involved in tumour growth, including VEGFR-1, VEGFR-2, and VEGFR-3, FGFR-1 through FGFR-4, PDGFR-alpha, RET, and KIT. By inhibiting VEGFR signalling, Lenvaxen suppresses the angiogenesis tumours depend on to form new blood vessels, while its inhibition of FGFR, PDGFR, RET, and KIT provides additional, complementary anti-tumour activity across several distinct cancer types.

This broad kinase-inhibition profile underlies Lenvaxen’s use both as a standalone treatment (in DTC and HCC) and in combination with immune checkpoint or mTOR-targeted therapies (in RCC and endometrial carcinoma), where the different mechanisms of each agent work together for a stronger overall anti-tumour effect.

Lenvaxen is taken as a once-daily oral capsule, with the exact dose built from a combination of capsule strengths tailored to the specific cancer type and companion therapy being used.

Indications for Lenvaxen (Lenvatinib)

Lenvaxen (Lenvatinib) is indicated for the following conditions:

Benefits of Lenvaxen (Lenvatinib) 10mg

How to Take Lenvaxen (Lenvatinib)

Monitoring and Dosage Adjustments

Regular monitoring is essential throughout Lenvaxen treatment. Your oncologist will monitor blood pressure closely, particularly during the first cycle, along with cardiac function, liver function tests, renal function, and urine protein. Monitoring also includes periodic thyroid function, serum calcium, and, where indicated, ECG monitoring for QT prolongation. Report any severe headache, chest pain, unusual bleeding, severe abdominal pain, decreased urination, muscle cramps, vision changes, confusion, or seizures to your doctor immediately.

Drug Interactions and Important Information

Use with caution alongside other medicines known to prolong the QTc interval, and inform your physician of any medications that affect blood pressure or clotting risk. When Lenvaxen is used with everolimus or pembrolizumab, refer also to the prescribing information for those agents, as they carry their own distinct warnings and monitoring requirements.

Lenvaxen can cause foetal harm and is not recommended during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception during treatment and for at least 30 days after the final dose; men should use effective contraception during treatment and for at least 30 days after the final dose. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Lenvaxen.

Side Effects and Precautions

Who Should Use Lenvaxen (Lenvatinib)?

Lenvaxen is suitable for adult patients with radioactive iodine-refractory differentiated thyroid cancer, unresectable hepatocellular carcinoma, advanced renal cell carcinoma (in combination with everolimus or pembrolizumab), or advanced endometrial carcinoma (in combination with pembrolizumab). It is prescribed by medical oncologists experienced in managing multikinase inhibitor therapy and its associated cardiovascular, hepatic, and renal risks. A thorough medical assessment including blood pressure, cardiac evaluation, liver and renal function, and thyroid function is required before initiating treatment.

Manufacturer: Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Lenvaxen under cGMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Lenvaxen is one of Everest’s specialty oncology products, offering a bioequivalent alternative to Lenvima by Eisai/Merck at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Lenvaxen (Lenvatinib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Lenvaxen (Lenvatinib) from Mediaid Pharmacy?

Lenvaxen represents one of the most versatile multikinase inhibitors in modern oncology, spanning thyroid, liver, kidney, and endometrial cancer. As the generic equivalent of Lenvima by Eisai/Merck, it delivers the same active ingredient, Lenvatinib, with the same proven multi-target inhibition mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under cGMP-compliant standards and distributed globally by Mediaid Pharmacy, Lenvaxen gives patients worldwide access to advanced targeted cancer therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Lenvatinib option with worldwide delivery, Lenvaxen from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Lenvaxen (Lenvatinib)